Valo SPAC Presentation Deck
Valo is rapidly scaling and executing its strategy with the goal of positioning
Opal as the standard technology platform upon which drugs are built
Powered by the Opal platform, Valo aspires to transform the biopharma industry
as what we believe is the first digitally-native fully integrated pharma. Valo is:
Leveraging Opal to achieve scalable activation and advancement of high
potential therapeutic programs
-
Optimizing portfolio and minimizing risk with existing pipeline of 15
active programs with high impact potential
Expecting myriad clinical development milestones in diverse areas in
the near-term¹
Aspiring to create a repeatable flow of 2-3 preclinical drug
candidates annually (substantial latent pipeline of programs)
CLINICAL DEVELOPMENT
Reg
Valo [1] Reflects management's 2021 goals
Comm
BIOLOGICAL
RWE
Diagnosis
Opal
PLATFORM
Phase III Phase II
DISCOVERY
Target
Discovery
Phasel
Preclinical
Target ID
Target
to Hit
Lead Opt.
Planning to scale external supply chain of programs to increase velocity of Opal's flywheel
We believe there is an opportunity for Opal to become the standard technology platform for drug
development via combination of partnerships and software solutions
Khosla Ventures has a reputation for betting on industry transformations and high growth companies. Combination
with Khosla represents recognition of Valo's execution to-date and transformative aspirations
THERAPEUTIC DESIGN
2Q21
34View entire presentation